Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VK2735 Drug · 1 trial · 1 indication
-Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo Subcutaneously (SC) weekly |
| VK2735 Dose Level 2 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly |
| VK2735 Dose Level 3 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously weekly |
| VK2735 Dose Level 4 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week |
| VK2735 Dose Level 5 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 6 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 7 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 8 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 9 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly |
| VK2735 Dose Level 10 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week |
| VK2735 Dose Level 11 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week |
| VK2735 Dose Level 12 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly |
| VK2735 Dose Level 14 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 orally once daily |
| VK2735 Dose Level 15 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 orally once daily |
| VK2735 Dose Level 16 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 orally once daily |
| VK2735 Dose Level 17 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by Placebo orally once weekly |
| VK2735 Dose Level 18 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by Placebo orally once daily |
| VK2735 Dose Level 13 | EXPERIMENTAL | VK2735 subcutaneously weekly followed by VK2735 orally weekly |
| Name | Type | Description |
|---|---|---|
| VK2735 Drug | DRUG | SC or oral once daily, once weekly, every other week, or monthly |
| Placebo | DRUG | SC or oral once daily or once weekly |
Inclusion Criteria: * Must be capable of giving a signed informed consent form (ICF). * Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opi...
VK2735 is an investigational small molecule being developed for the treatment of obese adults. It is in Phase 1 clinical development and is not approved for any indication. The program is led by Viking Therapeutics, Inc. and is being studied in adults with obesity without comorbidities.
VK2735 is being developed by Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company that trades on the Nasdaq under the ticker symbol VKTX. Viking Therapeutics is the sponsor of the Phase 1 clinical trial evaluating VK2735 in obese adults.
VK2735 is in Phase 1 clinical development. The only listed trial is a Phase 1 study in obese adults without comorbidities, and it is currently recruiting participants. VK2735 has not completed Phase 1 and is not approved by the FDA for any use.
VK2735 is being evaluated in a single Phase 1 trial, NCT07838740, titled A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities. The trial is recruiting, is placebo-controlled, randomized, and double-blind, and is expected to enroll 270 participants in the United States.
No. VK2735 is an investigational drug in Phase 1 clinical development and has not been approved by the FDA. It is being studied in obese adults without comorbidities under an active, recruiting Phase 1 protocol, and approval has not been granted for any indication.